Companies / Switzerland
Lonza Buys Cambrex's Biopharmaceutical Units
October 2006 | Company News AlertTo exploit the booming biopharmaceutical sector, Swiss contract manufacturing organisation (CMO) Lonza has agreed to purchase two businesses from US firm Cambrex. Lonza is paying US$460mn for its Research Bioproducts division and its Microbial Biopharmaceuticals business. The transaction further increases Lonza's transition into a life science company, which it first announced two years ago, and the deal reduces the Basel-based group's reliance on the highly competitive production of traditional pharmaceuticals for
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
